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Abstract: Mannose-6-phosphate (M6P) is recognized by the 
mannose-6-phosphate receptor and plays an important role in the 
transport of cargo to the endosomes, making it an attractive tool to 
improve endosomal trafficking of vaccines. We here describe the 
assembly of peptide antigen conjugates carrying clusters of mannose-
6-C-phosphonates (M6Po). The M6Po’s represent stable M6P mimics 
that are resistant to cleavage of the phosphate group by endogenous 
phosphatases. Two different strategies for the incorporation of the 
M6Po clusters in the conjugate have been developed: the first relying 
on a “post-assembly” click approach employing an M6Po bearing an 
alkyne functionality; the second hinges on an M6Po C-glycoside 
amino acid building block that can be used in solid-phase peptide 
synthesis. The generated conjugates were further equipped with a 
TLR7-ligand to stimulate dendritic cell (DC) maturation. While antigen 
presentation is hindered by the presence of the M6Po clusters, the 
incorporation of the M6Po clusters leads to increased activation of 
DCs, demonstrating their potential in improving vaccine adjuvanticity 
by intraendosomally active TLR-ligands. 
Introduction 
Carbohydrates play an important role in many biological 
processes, such as cell-cell communication, pathogen recognition 
and protein folding. Mannose-6-phosphate (M6P), a D-
mannopyranose bearing a phosphate group at the C-6 position, 
serves as a signaling moiety on the termini of glycan branches 
mounted on newly synthesized proteins in the trans-Golgi network 
and is essential for the transportation of these proteins to the late 
endosomes and lysosomes. The mannose-6-phosphate receptor 
(MPR), a P-type lectin, plays an important role in this 
transportation through binding to M6P.[1,2] There are two members 
of this lectin family: the cation-dependent mannose-6-phosphate 
receptor (CD-MPR) and the cation-independent mannose-6-
phosphate receptor (CI-MPR). The latter has a high affinity for 
ligands containing multiple M6Ps due to the presence of two M6P 
binding domains, which can simultaneously bind two M6Ps.[3–5] A 
small fraction of MPRs can be found on the cell surface of which 
only CI-MPR binds and internalizes M6P-bound substrates.[6] 
Therefore, the CI-MPR is an efficient tool for targeted delivery to 
the endosomes, as was shown by the conjugation of M6P 
analogues to acid α-glucosidase leading to improved delivery of 
this enzyme in the treatment of the lysosomal myopathy Pompe 
disease.[7] The MPR has also been exploited as a drug delivery 
system for cancer therapy,[8,9] for example, doxorubicin was 
delivered via mannose-6-phosphate-modified human serum 
albumin as carrier and N-hexanoyl-D-erythro-sphingosine with 
M6P-functionalized liposomes.[10,11] Our group has previously 
reported that a cathepsin inhibitor that is covalently attached to an 
M6P cluster could effectively be delivered into the endolysosomal 
pathway.[12]  
The activity of peptide-based anti-cancer vaccines may be 
enhanced by the targeted delivery of these antigens to antigen 
presenting cells. In this context, mannosylated antigens, destined 
for the mannose receptor or DC-SIGN present on dendritic cells 
(DCs), have been widely explored.[13–16] We, therefore, reasoned 
that conjugate vaccines in which an M6P moiety is covalently 
bound to an antigenic peptide might be targeted effectively to 
immune cells expressing the MPR, leading to improved uptake 
and more efficient delivery to the lysosomes where the cargo is 
processed for MHC loading, ultimately resulting in enhanced 
antigen presentation. Since dephosphorylation by endogenous 
phosphatases is one of the potential drawbacks of the use of M6P, 
several stable M6P analogues have previously been evaluated, 
such as a malonyl ether, a malonate or an isosteric C-
phosphonate ester.[17,18] The C-phosphonate proved to be a 
stable and effective replacement for the phosphate monoester.[19]  
We here describe the incorporation of a cluster of mannose-6-
phosphonates (M6Po) in two types of peptide antigen-conjugates 
(1-8, Figure 1), wherein two different M6Po building blocks, 9 and 
10, respectively, are used to construct M6Po-clusters and 
conjugate them to either the N- or the C-terminus of a synthetic 
long peptide (SLP). In this study, two different ovalbumin derived 
SLPs are used: DEVA5K (DEVSGLEQLESIINFEKLAAAAAK), 
which harbours the MHC-I presented epitope SIINFEKL, and 
HAAHA (ISQAVHAAHAEINEAGRK), which contains an MHC-II 
epitope. Our goal is to enhance the immune response by 
increasing endosomal trafficking of the peptide vaccine via the 
MPR which led to the design of bis-conjugates (2, 4, 6, and 8) in 
which the Toll-like receptor 7 ligand (TLR7L) 2-alkoxy-8-oxo- 
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Figure 1. Structures of the O-M6Po conjugates 1-4, C-M6Po conjugates 5-8, and building blocks 9 and 10.
adenine is added at either the N- or the C-terminus of the M6Po-
SLP.[20,21] We coupled an α-configured spacer,[12,18,22] carrying an 
alkyne function to the O-M6Po building block 9 to allow for the 
copper mediated 1,3-dipolar cycloaddition to azide-functions 
incorporated in the SLP, while C-M6Po building block 10 was 
used to generate the HAAHA-conjugates via solid-phase peptide 
synthesis (SPPS). This building block is a C-analogue[23] of O-
M6Po, in which the anomeric oxygen is replaced with a CH2, 
preventing hydrolysis under the acidic conditions used in SPPS. 
An additional advantage of this SPPS-compatible building block 
is the possibility to prepare conjugates of peptides that are not 
suitable for copper mediated 1,3-dipolar cycloaddition. It also 
allows one to incorporate azide or alkyne click handles in 
conjugate vaccine constructs that can be exploited for labelling or 
visualization purposes. 
We here report the synthesis and immunological evaluation of 
these dual conjugated peptide vaccine constructs. 
 
Results and Discussion 
Synthesis of M6Po-conjugates 
The first type of O-M6Po conjugates comprises the six-fold 
addition of α-propargyl mannose-6-phosphonate (O-M6Po) 
building block (9) to azide containing peptides. Synthesis of the 
required building block 9 started from propargyl-D-mannose 11 
(Scheme 1A). As we found that the use of para-methoxybenzyl 
ethers for the protection of the secondary alcohols led to the 
formation of a 3,6-ether bridge when the C-6-hydroxyl was 
triflated, to enable the subsequent substitution by a phosphonate 
anion (See supporting information Scheme S1), we placed an 
isopropylidene group over the 2,3-cis-diol system to prevent this 
intramolecular side reaction.[24,25] Thus, tritylation of 11 and 
subsequent installation of the isopropylidene gave 13, of which 
the remaining alcohol was masked as a p-methoxybenzyl ether to 
give the fully protected mannose 14. The alkyne in 14 was 
protected with a TMS group using TMSCl and n-BuLi at -78°C. 
Removal of the trityl in the thus obtained 15 with a catalytic 
amount of p-toluenesulfonic acid in DCM/MeOH was 
accompanied by partial removal of the isopropylidene ketal. 
Reinstallation of the isopropylidene and subsequent deprotection 
of the mixed ketal simultaneously formed on the primary alcohol 
gave 16 in 98% over three steps. Alcohol 16 was treated with Tf2O 
and pyridine at -40°C[26] and the obtained crude triflate was added 
to a mixture of dimethyl methylphosphonate and n-BuLi in THF at 
-70°C, yielding compound 17 in 72% over two steps. Removal of 
the TMS protecting group gave 18, which was transformed into 
key building block 9 by a two-step deprotection sequence. The 
deprotection of the phosphonate using TMSBr was followed by 
the removal of the p-methoxybenzyl and isopropylidene groups 
by treatment with AcOH/H2O at 90°C to deliver key building block 
9 in 27% yield over 15 steps starting from D-mannose. 
En route to mannose-6-phosphonate SPPS building block 10 
(Scheme 1B), the trityl group of known compound 19[23] was 
removed as described above to give alcohol 20 in 72% over three 
steps. Conversion of 20 to the primary triflate, followed by 
nucleophilic substitution with the anion of di-tert-butyl 
methylphosphonate[27] gave phosphonate 21 in 72% over two   
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Scheme 1. Synthesis of alkyne building blocks 9 and 10. Reagents and conditions: a) i. Ac2O, pyridine; ii. propargyl alcohol, BF3ꞏOEt2, 50°C; iii. NaOMe, MeOH, 
70% over three steps; b) TrtCl, Et3N, DMF, 60°C, 83%; c) p-toluenesulfonic acid, 2,2-dimethoxypropane, 87%; d) p-methoxybenzyl chloride, NaH, DMF, 95%; e) 
TMSCl, n-BuLi, THF, -78°C, 97%; f) i. p-toluenesulfonic acid, DCM/MeOH; ii. p-toluenesulfonic acid, 2,2-dimethoxypropane; iii. 1 M HCl, EtOAc, 0°C, 98% over 
three steps: g) i. Tf2O, pyridine, DCM, -40°C; ii. n-BuLi, dimethyl methylphosphonate, THF, -70°C to -50°C, 72% over two steps; h) TBAF, THF, quant.; i) i. TMSBr, 
pyridine, MeCN; ii. AcOH/H2O, 90°C, 81% over two steps; j) i. p-toluenesulfonic acid, DCM/MeOH; ii. p-toluenesulfonic acid, 2,2-dimethoxypropane; iii. 1 M HCl, 
EtOAc, 0°C, 75% over three steps; k) i. Tf2O, pyridine, DCM, -40°C; ii. n-BuLi, di-tert-butyl methylphosphonate, THF, -70°C to -50°C, 72% over two steps; l) i. methyl 
acrylate, CuI, Grubbs 2nd gen. catalyst, DCE, 60°C; ii. NaBH4, RuCl3, MeOH, DCE, 45°C, 72% over two steps; m) LiOH, THF/H2O, quant; n) Fmoc-L-Lys-OMe, 
HCTU, DIPEA, DMF, 86%; o) LiOH, THF/H2O, 0°C, 80%. 
steps on 3 mmol scale.[28] Cross metathesis with methyl acrylate, 
followed by the reduction of the double bond with NaBH4 and 
ruthenium trichloride then resulted in compound 22.[29,30] 
Hydrolysis of the obtained methyl ester, was followed by 
condensation with Fmoc-L-Lys-OMe and subsequent treatment of 
24 with LiOH at 0°C,  which left the Fmoc group unaffected, then 
delivered the key SPPS building block 10 in 80% yield.  
Next, the assembly of the (O-M6Po)6-SIINFEKL conjugates was 
undertaken. Immobilized peptides 25 and 28 were prepared 
through standard SPPS HCTU/Fmoc chemistry using Tentagel S 
Ram as solid support (Scheme 2A). The C-terminal lysine of 25 
was protected with a MMT group since we aimed to make M6Po-
peptide conjugates as well as conjugates containing both an 
M6Po-cluster and a TLR7-ligand. TFA/TIS/H2O (95/2.5/2.5 v/v/v) 
treatment removed all protecting groups and cleaved the peptides 
from the resin to give peptides 26 and 29 in 1% and 6% yield 
respectively, after purification. Alternatively, the MMT protecting 
group at the C-terminal lysine of 25 was selectively deprotected 
using a cocktail of TFA/TIS/DCM (2/2/96 v/v/v). The released 
amine was subsequently coupled with the spacer 33 and the Boc-
protected TLR7-ligand building block 34.[21] After  deprotection, 
release from the resin and RP-HPLC purification peptides 27 and 
30 were obtained in a 2% yield. Coupling of O-M6Po building 
block 9 to peptides 26, 27, 29 and 30 was performed using a 
cocktail of CuSO4, sodium ascorbate and 
tris(benzyltriazolylmethyl)amine in DMSO/H2O,[31] with the 
addition of a 20 mM Tris/150 mM NaCl buffer. After RP-HPLC, 
conjugates 1-4 were obtained in 5% (0.3 mg), 18% (0.9 mg), 18% 
(1.0 mg) and 31% (3.3 mg) yield respectively. 
The HAAHA peptide contains two histidines, which can 
coordinate to copper and thereby inhibit the reduction of Cu(II) to 
Cu(I).[32] Therefore, conjugates 5-8 were generated by an online   
SPPS synthesis (Scheme 2B) using C-M6Po building block 10, 
which is equipped with acid-labile protecting groups that can be
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Scheme 2. Synthesis of A) O-M6Po conjugates 1-4 and B) C-M6Po conjugates 5-8. Reagents and conditions: a) i. 20% piperidine, DMF; ii. Fmoc SPPS cycle for 
K(N3)-K(N3)-K(N3)-K(N3)-K(N3)-K(N3)-DEVSGLEQLESIINFEKLAAAAAK; iii. 20% piperidine, DMF; iv. Ac2O, DIPEA, DMF; b) TFA/TIS/H2O (95/2.5/2.5 v/v/v), 3h; c) 
RP-HPLC; d) 9, 20 mM Tris/150 mM NaCl buffer, CuSO4/NaAsc/TBTA, H2O/DMSO; e) TFA/TIS/DCM (2/2/96 v/v/v); f) i. {2-[2-(Fmoc-amino)ethoxy]ethoxy}acetic 
acid, HCTU, DIPEA, DMF; ii. 20% piperidine, DMF; iii. 4-((2-butoxy-6-((tert-butoxycarbonyl)amino)-8-oxo-7,8-dihydro-9H-purin-9-yl)methyl)benzoid acid, HCTU, 
DIPEA, DMF; g) i. 20% piperidine, DMF; ii. Fmoc SPPS cycle for DEVSGLEQLESIINFEKLAAAAAK-K(N3)-K(N3)-K(N3)-K(N3)-K(N3)-K(N3); iii. 20% piperidine, DMF; 
h) Ac2O, DIPEA, DMF; i) i. 20% piperidine, DMF; ii. Fmoc SPPS cycle for ISQAVHAAHAEINEAGRK; iii. 20% piperidine, DMF; iv. 10, HCTU, DIPEA, DMF; v. 5x 
repeat of iii. and iv.; vi. 20% piperidine, DMF; vii. Ac2O, DIPEA, DMF; j) AcOH/TFE/DCM (1/2/7 v/v/v); k) i. 20% piperidine, DMF; ii. 10, HCTU, DIPEA, DMF; iii. 5x 
repeat of i. and ii.; iv. 20% piperidine, DMF v. Fmoc SPPS cycle for ISQAVHAAHAEINEAGRK; iii. 20% piperidine, DMF; Yield peptides and conjugates: 26) 4.6 mg, 
1%; 27) 4.0 mg, 2%; 29) 17.4 mg, 6%; 30) 8.2 mg, 2%; 1) 0.3 mg, 5%; 2) 1.0 mg, 18%; 3) 0.9 mg, 18%; 4) 3.3 mg, 31%; 5) 13.3 mg, 10%; 6) 11.0 mg, 8%; 7) 3.1 
mg, 2%; 8) 17.0 mg, 11%. 
removed at the end of the SPPS concomitantly with all other acid-
labile peptide protecting groups and release of the peptide from 
the resin. Tentagel S Ram resin was elongated with 
ISQAVHAAHAEINEAGRK using automated SPPS, of which the 
lysine(MMT) at the C-terminus will be used for elongation at a 
later stage of the synthesis. Six consecutive coupling and Fmoc 
removal cycles with building block 10 gave immobilized peptide 
31. Peptide 32, bearing the C-M6Po cluster at the C-terminal end, 
was generated by assembling the hexa-C-M6Po peptide through 
manual couplings of building block 10, followed by automated 
SPPS to assemble the rest of the peptide. Immobilized and 
protected peptides 31 and 32 were deprotected and 
10.1002/cbic.202000538
Ac
ce
pt
ed
 M
an
us
cr
ip
t
ChemBioChem
This article is protected by copyright. All rights reserved.
FULL PAPER    
5 
 
simultaneously cleaved from the resin with the TFA/TIS cocktail 
to provide conjugates 5 (13.3 mg) and 7 (3.1 mg) after purification 
by RP-HPLC in 10% and 8% yield respectively, demonstrating the 
suitability of 10 for SPPS. To obtain conjugate 6, bearing the 
TLR7-ligand, the MMT-group in 31 was selectively removed with 
a cocktail of AcOH/TFE/DCM (1/2/7 v/v/v). The obtained free 
amine was elongated with spacer 33 and Boc-protected TLR7-
ligand building block 34 to give conjugate 6 (11.0 mg) in 2% yield, 
after removal of all the protecting groups, cleavage from the resin 
and RP-HPLC purification. The same sequence of events was 
applied to the N-terminal amine in immobilized peptide 32 to 
afford conjugate 8 (17.0 mg) in 8% yield. 
 
Immunological evaluation 
We assessed the capacity of the conjugates 1-8 to induce 
maturation of dendritic cells (DCs) and stimulate antigen 
presentation (Figure 2). In these assays reference compounds 
35-40, lacking the mannose-6-phosphonate clusters, were used 
as a control (See supporting information Scheme S2). The 
activation of DCs can be measured by the detection of the 
production of interleukin-12 (IL-12). First, the O-M6Po conjugates 
1-4 were evaluated (Figure 2A). To this end, murine bone 
marrow/derived DCs were stimulated for 24 hours with the 
compounds and the amount of secreted IL-12 was measured in 
the supernatant. As expected, conjugation with solely a cluster of 
M6Po (as in conjugates 1 and 3) does not induce DC maturation. 
In contrast, the TLR7-ligand SLP conjugates (36 and 37) induce 
IL12 production due to stimulation of the TLR7 receptor. 
Interestingly, the conjugates carrying the M6Po-cluster and the 
TLR7-ligand (2 and 4) induced a stronger activation of the DCs 
than their counterparts solely bearing a TLR7-ligand (i.e., SLP-
conjugates 36 and 37). The position of the M6Po-clusters and 
TLR7 ligand in these conjugates did not seem to influence the 
activity of the conjugates. Similar effects were observed for the 
conjugates 6 and 8 with the C-M6Po-clusters, indicating that the 
C-mannosyl-6-C-phosphonate is an adequate mimic of its O-
mannosyl counterpart and that the enhanced stimulatory effect is 
independent of the peptide sequence (Figure 2B, see also 
supporting Figure S1). Overall this indicates that conjugation of 
the M6Po-cluster to a peptide antigen adjuvanted with a TLR7-
ligand enhances DC maturation by improving uptake of the 
conjugate and/or trafficking of the conjugates to the endosomally 
located TLR7 receptor.  
Processing of the two peptides was investigated by assessing 
presentation of the SIINFEKL epitope on MHC-I by the DCs to 
CD8+ T cells and presentation of the helper epitope (HAAHA) to 
CD4+ T cells. For the former assay, a hybridoma (B3Z) CD8+ T 
cell line was used, while the latter employed an OTIIZ hybridoma 
CD4+ T cell line. As can be seen in Figures 2C and 2D, attachment 
of the TLR7-ligand to the SLPs led to the enhanced presentation 
of the antigens (See for example 35 vs. 36/37 and 38 vs. 40), 
however the inclusion of the M6Po-clusters hampered 
presentation through both the MHC class I and MHC class II 
pathways (See for example 36 vs. 4, 37 vs. 2 and 40 vs. 6). This 
indicates that the conjugation of M6Po-clusters affects 
intracellular trafficking or processing of the peptides. 
 
Conclusion 
In conclusion, we have described the development of two 
mannose-6-C-phosphonate (M6Po) building blocks which allow 
for stabilized M6P-analogues to be incorporated in peptide 
sequences to target the M6P receptor. To prevent 
dephosphorylation by endogenous phosphatases, the O-
phosphate in the naturally occurring mannose-6-phosphate was 
replaced by a C-phosphonate moiety. The first building block 
carries an O-propargyl group at the anomeric center of the 
mannose-6-C-phosphonate, which allows for the incorporation of 
the M6Po in peptide sequences through an azide-alkyne click 
reaction. The second building block, a C-mannoside, was 
designed and synthesized for application in solid-phase peptide 
synthesis. The acid-stable anomeric linkage and protecting 
groups used enabled the streamlined in-line incorporation of the 
building block during SPPS. With the building blocks, various 
peptide conjugates were assembled, containing either an MHC-I 
or an MHC-II epitope, an M6Po-cluster presenting six mannose-
6-phosphonates, and a TLR7-ligand. Although immunological 
evaluation has shown that conjugation of the M6Po-clusters 
inhibits antigen presentation, the ability of the TLR7-ligand 
conjugates to induce DC maturation was significantly improved. 
While the M6Po clusters effectively trafficked the conjugates to 
the endosome, where the conjugates interacted with TLR7 
receptor, the processing of the conjugates was impeded by the 
M6Po-clusters. Future conjugates will be designed featuring 
cleavable linkers that allow for the release of the clusters during 
endolysosomal processing, effectively liberating the incorporated 
peptide antigens for presentation. 
Keywords: C-glycoside • mannose-6-phosphate receptor • 
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the OTIIZ hybridoma cell line was used to detect presentation of the HAAHA epitope. B3Z or OTIIZ activation was determined by colorimetric reaction of the lacZ 
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concentrations were calculated by 2-way ANOVA followed by multiple comparison and Tukey corrections. * p<0.05, ** p< 0.01, *** p<0.001, **** p<0.0001.and 
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We report the synthesis of two mannose-6-C-phosphonate (M6Po) building blocks that can be incorporated in a conjugate via either a 
“post-assembly” click or an online solid-phase peptide synthesis approach to improve endosomal trafficking of vaccines. The generated 
M6Po-conjugates, which were also equipped with a TLR7-ligand, were able to enhance the immune response by activation and 
maturation of dendritic cells. 
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